FDA Determines Regulatory Review Period for ZYDELIG Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially set a regulatory review period for ZYDELIG, a new drug application (NDA 206545), following a request from the US Patent and Trademark Office (USPTO) to extend a patent claiming the human drug product.